New User Fees Will Expedite Med Device Reviews

Source: MassDevice (7/9/12)

"The deal boosted the user fees from $295 million over five years to $595 million in exchange for the FDA meeting performance goals."

MassDevice

President Barack Obama signed the Food & Drug Administration Safety & Innovation Act, enacting the doubling of the user fees medical device companies pay to have the FDA review their products.

President Barack Obama put his pen to the Food & Drug Administration Safety & Innovation Act today, making it the law of the land that the user fees medical device companies pay to have the FDA review their products more than doubles.

The med-tech industry and the federal watchdog agency spent months hashing out the terms of the deal, which ultimately boosted the user fees from $295 million over five years to $595 million, in exchange for the FDA meeting performance goals. . .View Full Article

Biotech Enters Agreement with Co. Behind Tegoprubart
Source: Dr. Joseph Pantginis (07/14/2025)

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report.

Biotech Boasts Compelling Pipeline
Source: Dr. Andre Uddin (06/23/2025)

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) is exploring financing options with some potential sources of capital, noted a Research Capital Corp. report.

Analyst Shares Thoughts After Microdisplay Co.'s Demo Day
Source: Jaeson Schmidt (06/23/2025)

Kopin Corp.'s (KOPN:NASDAQ) display and optical technologies as well as its products are impressive, noted a Lake Street Capital Markets report.

Interim Data From TID Trial Are Positive
Source: Streetwise Reports (05/15/2025)

Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit.

One Co. With Cell Holding Device Stands Out in T1D Space
Source: Dr. Joseph Pantginis (04/28/2025)

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report.